Basic & Clinical Medicine ›› 2023, Vol. 43 ›› Issue (5): 833-836.doi: 10.16352/j.issn.1001-6325.2023.05.0833

• Mini Reviews • Previous Articles     Next Articles

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia

XIANG Caixia1, HUANG Bintao1*, HAO Jian2   

  1. 1. Department of Hematology; 2. Department of Nephrology,the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, China
  • Received:2022-03-14 Revised:2022-11-16 Online:2023-05-05 Published:2023-04-26
  • Contact: *

Abstract: The anti-apoptotic protein Bcl-2 inhibitor venetoclax (Ven) can significantly improve the remission rate and long-term survival of elderly and relapsed/refractory acute myeloid leukemia(AML) patients who are not sensitive to intensive chemotherapy. TP53/FLT3 mutation, abnormal energy metabolism of fatty acids and amino acids, high expression of Mcl-1 protein and activation of ferroptosis program occur during clinical treatment are all involved in the development of Ven resistance and leukemia progression. Further exploration of the mechanisms leading to Ven resistance in myeloid leukemia may help to inhibit the development of Ven resistance and continuously improve the long-term survival of leukemia patients.

Key words: acute myeloid leukemia, venetoclax(Ven), apoptosis, ferroptosis

CLC Number: